WE CLAIM:
1. A composition for inhibiting GMF-β phosphorylation in cells, comprising:
an effective amount of compound of Formula (I):
or a pharmaceutically acceptable salt thereof.
2. The composition of claim 1, wherein the effective amount is in the range of 1 ng/ml to 1 g/ml.
3. The composition of claim 1, wherein the compound of Formula (I) binds to GMF-β with a binding affinity in the range of -6.5 to -5.5 kcal/mol.
4. The composition of claim 3, wherein the compound interacts with Arg24, Thr27, Ser72, Arg81, Val82, and Ser83 of GMF-β and inhibits phosphorylation of Ser83 and Thr27 of GMF-β.
5. The composition of claim 1, where in the compound shows cell permeability of at least 500 nm/sec, oral absorption of at least 80%, blood brain barrier permeability in the range of -0.7 to -0.4.
6. The composition of claim 1, wherein the cells are neurons, glial cells, endothelial cells, fibroblasts, pericytes, macrophages, monocytes, leukocytes, plasma cells, mast cells, adipocytes, cancer cells, astrocytes, mast cells, peripheral blood

mononuclear cells (PBMCs), or a combination thereof.
7. The composition of claim 1, wherein the compound suppresses p38MAPK and NFκB expression in cells.
8. A kit comprising the composition of claim 1 and instructions for use.
9. A pharmaceutical formulation, comprising: an effective amount of compound of Formula (I):
or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier, wherein the formulation is effective against a central nervous system (CNS) disease or disorder.
10. A method of inhibiting GMF-β phosphorylation in cells, comprising: adding an effective amount of compound of Formula (I):
or a pharmaceutically acceptable salt thereof to cells.